Objective To summarize the effect of self-setting CPC on the repair of bone defect after tumor resection in children. Methods From December 1998 to December 2006, 32 patients with benign bone tumor were treated, and the bonedefect was repaired by CPC. Among them, there were 21 males and 11 females, aged 4-14 years old (9.8 on average). The course of disease was 3-18 months. There were 12 cases of non-ossifying fibroma, 8 of bone cyst, 7 of osteoid osteoma and 5 of fibrous dysplasia. The bone defect was located in femur in 15 cases, in tibia in 8 cases, in humerus in 6 cases and in other positions in 3 cases. The range of bone defect was 2.0 cm × 1.5 cm × 1.0 cm - 10.0 cm × 5.0 cm × 4.0 cm. CPC spongiosa granules of 3-23 g were filled in 26 cases, including 3 children with pathologic fracture and internal fixation with plate, and injectable CPC of 5-20 mL was filled in 6 bone cyst cases. Results Thirty-two patients obtained heal ing by first intertion. All the patients were followed up for 12-48 months (23.5 months on average). No allergic reaction, toxicity, rash or high fever was found after operation. There was no pain or pruritus at the incisions. The X-ray films showed that the implanted CPC began to fuse with the host bone 4-9 months (7 month on average) after operation. The internal fixation was removed within 6-12 months of operation. And CPC spongiosa granules were absolutely absorbed within 8-36 months of operation. However, injectable CPC could be found 4 years after operation. The children’s l imbs could do normal exercises. Finally, bone matrix grew well and no recurrence was found. Conclusion CPC in repairing bone defect after benign bone tumor in children is a safe, economical, convenient and non-toxic method.
To observe the clinical effect and safety of the nano-hydroxyapatite/polyamide 66 (n-HA/PA66) composite in repairing the bone defects due to benign bone tumors. Methods From January 2003 to May 2005, 38 patients (21 males, 16 females; age, 19-58 years, averaged 38.5 years) with the bone defects due to benign bone tumors were treated with the n-HA/PA66 grains. Among the 37 patients, 11 had fibrous dysplasia, 14 had bone cyst, 10 had giant cell tumor of the bone (Grade Ⅰ), and 2 had enchondroma. The tumors ranged in size from 1.0 cm×0.7 cm×0.4 cm to 10.0 cm×4.0 cm×3.0 cm, with the location of the proximal femur in 12 patients, the distal femur in 7, the proximal tibia in 9, the proximal humerus in 5, the phalanges of the finger in 2, the metacarpal bone in 1,and the calcaneus in 1. Allthe benign bone tumors underwent the curettage treatment, and then the tumor cavities were filled up with the n-HA/PA66 grains. The incision healing, local inflammatory reaction, rejection, toxic reaction, tumor cavity healing, and function recovery of the limbs were all observed after operation. Results All the patients were followed up for 5-33 months, and all the incisions healed by the first intention except 1 incision, which developed infection. The inflammatory reaction was mild, with no reection or general toxic reaction. At 3 to 5.5 months(mean 4 months) after operation, osteogenesis wasfound in the space filled with the n-HA/PA66 grains. Eight months after operation, the patients’ lower limbs could bear weights; 5 months after operation, the upper limbs could complete daily work. Conclusion The n-HA/PA66 grains have great biological safety, good biocompatibility, and good bone conduction, which aregood materials for the bone repair and reconstruction, and can be safely, andeffectively used for repairing the bone defects due to benign bone tumors．
It is extremely necessary to find an ideal filling material for the treatment of benign bone defect, particularly those benign osteolytic defect in children with a comparatively large cavity. From July, 1995 to December, 1996, 10 cases of benign osteolytic bone defects were treated, in which 5 cases of benign osteolytic defects, 3 cases of bone cysts, 1 case of fibrous dysplasia of bone and 1 case of non-ossifying fibroma. After through curettage of the cavity, the natural non-organic bone in cube-shaped was used to fill the prepared cavity. The results showed that the activities of the patients resumed normal in 3 to 6 months after operation. The roentgenographic examination after operation showed that the lucent spaces between NNB cubes disappeared with obvious new bone formation and the bony cavity was obliterated with newly-formed bone. There was no recurrence of the lesion during a follow-up of 7 to 24 months. It was concluded that to treat the osteolytic defect of bone with NNB was a method of choice. The new bone formation appeared early in large amount and increased rapidly.
Objective To compare the healing process and clinical results of bioactive glass and allogenic bone in the repair of bone defects after benign bone tumor curettage. Methods Between November 2011 and December 2012, 20 patients with benign bone tumor received bioactive glass and allogenic bone for repair of bone defects after benign bone tumor curettage. There were 17 males and 3 females, aged 9-68 years (median, 18.5 years). The mean course of disease was 3.3 months (range, 1-9 months). Pathological examination revealed that there were 7 cases of chondroblastoma, 5 cases of bone cyst, 2 cases of non-ossifying fibroma, 2 cases of enchondroma, 1 case of vascular tumor of bone, 1 case of lipoma of bone, 1 case of osteoid osteoma, and 1 case of chondromyxoid fibroma. The lesion located at the femur in 5 cases, at the tibia in 11 cases, at the humerus in 1 case, at the calcaneus in 2 cases, and at the talus in 1 case. The bioactive glass and allogenic cancellous bone were implanted in the cavity at the same time. The Musculoskeletal Tumor Society (MSTS) function evaluation score was used for evaluation of postoperative limb function. According to the imaging and clinical benefit, the healing processes of two kinds of implants were evaluated. The healing rate and healing time were compared. The distribution of the bioactive glass was divided into two layers: the layer close to host bone and the layer close to allogenic bone. The bone ingrowth time and bone resorption time in different layers were evaluated and compared. Results All cases were followed up 12-42 months (mean, 34.5 months). All incisions healed by first intention. There were no complications of wound infection or deep infection, rejection, nonunion of bone, fracture at bone graft site, and collapsing of articular surface. There was no tumor recurrence during follow-up. The mean MSTS functional score was 29.5 (range, 28-30) at last follow-up. Complete healing was observed in 11 cases and healing in 9 cases. The healing rates of two kinds of implants were both 100%. The healing time of bioactive glass and allogenic bone was (4.7±1.3) months and (5.2±1.6) months, respectively, showing no significant difference (t=-1.240, P=0.244). The bone ingrowth time and the bone absorption time were (3.6±0.9) months and (3.7±1.0) months in the layer close to host bone and were (4.2±1.3) months and (4.2±1.3) months in the layer close to allogenic bone, all showing no significant difference (t=1.785, P=0.097; t=1.476, P=0.172). Conclusion For the repair of bone defects after benign bone tumor curettage, bioactive glass can achieve satisfactory healing result and has good safety.